keyword
MENU ▼
Read by QxMD icon Read
search

gastrointestinal stromal tumour

keyword
https://www.readbyqxmd.com/read/28900473/resection-of-rectal-gist-using-a-novel-technique-a-report-of-two-cases
#1
Osama Eldamshety, Islam H Metwally, Elsayed Ghoneem, Wagdi F Elkashef
Rectal gastrointestinal stromal tumours (GISTs) are uncommon tumours and usually present with large sizes. We present two cases of rectal GIST. Imatinib was used in the setting of neoadjuvant and adjuvant therapy. Both tumours were resected transanally by the transanal endoscopic operation (TEO) platform. Oncosurgeons are recommended to implement sphincter-sparing surgeries for these cases.
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28882125/evidence-mapping-based-on-systematic-reviews-of-therapeutic-interventions-for-gastrointestinal-stromal-tumors-gist
#2
Mónica Ballesteros, Nadia Montero, Antonio López-Pousa, Gerard Urrútia, Ivan Solà, Gabriel Rada, Hector Pardo-Hernandez, Xavier Bonfill
BACKGROUND: Gastrointestinal Stromal Tumours (GISTs) are the most common mesenchymal tumours. Currently, different pharmacological and surgical options are used to treat localised and metastatic GISTs, although this research field is broad and the body of evidence is scattered and expanding. Our objectives are to identify, describe and organise the current available evidence for GIST through an evidence mapping approach. METHODS: We followed the methodology of Global Evidence Mapping (GEM)...
September 7, 2017: BMC Medical Research Methodology
https://www.readbyqxmd.com/read/28842575/treatment-patterns-efficacy-and-toxicity-of-regorafenib-in-gastrointestinal-stromal-tumour-patients
#3
Gustavo Schvartsman, Michael J Wagner, Behrang Amini, Chrystia M Zobniw, Van Anh Trinh, Andrea G Barbo, Heather Y Lin, Wei-Lien Wang, Anthony Paul Conley, Vinod Ravi, Dejka M Araujo, Maria Alejandra Zarzour, Robert S Benjamin, Shreyaskumar Patel, Neeta Somaiah
Regorafenib was approved as third-line therapy for advanced Gastrointestinal Stromal Tumour (GIST) at a starting dose of 160 mg daily 3 weeks on, 1 week off, based on improvement in progression free survival over placebo (4.8 vs. 0.9 months), but the response rate was low at 4.5%. Given the high toxicity rate in GIST patients, there is variability in the post-marketing dosing of regorafenib. We aimed to summarize our experience regarding prescribing patterns, efficacy and toxicity of regorafenib and determine the role of response assessment by Choi criteria in GIST patients...
August 25, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28839880/gastrointestinal-stromal-tumours-gists-an-insight-into-clinical-practice-with-review-of-literature
#4
M J McDonnell, S Punnoose, Y K S Viswanath, N J Wadd, A Dhar
BACKGROUND: Gastrointestinal stromal tumours (GISTs) are rare mesenchymal tumours of the gastrointestinal tract. We retrospectively reviewed the clinical management of all patients with GIST presenting to a regional multidisciplinary upper gastrointestinal cancer group in the north of England. METHODS: Clinical, pathological, immunohistochemical treatment strategies, follow-up and outcome data on all patients with GIST between 2007 and 2012 were reviewed. Tumours were categorised by risk according to the National Institutes of Health (NIH) and AFIP models...
January 2017: Frontline Gastroenterology
https://www.readbyqxmd.com/read/28761758/the-european-society-for-medical-oncology-magnitude-of-clinical-benefit-scale-field-tested-in-infrequent-tumour-entities-an-extended-analysis-of-its-feasibility-at-the-medical-university-of-vienna
#5
Barbara Kiesewetter, Markus Raderer, Gerald W Prager, Thorsten Fuereder, Christine Marosi, Matthias Preusser, Michael Krainer, Gottfried J Locker, Thomas Brodowicz, Christoph C Zielinski
BACKGROUND: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a new tool to quantify the clinical benefit that may be anticipated from a novel anticancer treatment. We present here an analysis on the feasibility of the ESMO-MCBS in less frequent tumour entities. METHODS: This study evaluates the practicability of the ESMO-MCBS for metastatic neuroendocrine tumours (NETs), soft tissue sarcomas, glioblastoma, thyroid cancer, pancreatic cancer, head/neck cancer, urothelial cancer and ovarian cancer at the Medical University Vienna...
2017: ESMO Open
https://www.readbyqxmd.com/read/28751509/giant-oesophageal-gastrointestinal-stromal-tumour-presenting-with-dyspnoea-and-clubbed-fingers
#6
Yurie Yamamoto, Yosuke Sasaki, Michio Kougame, Naobumi Tochigi
Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms of the gastrointestinal tract originating from the interstitial cells of Cajal. Giant oesophageal GISTs are rare since the oesophagus is rarely the primary site of GISTs, and they are usually diagnosed early due to complaints such as dysphagia. We present the case of a giant oesophageal GIST presenting with prominent clubbing. The case underlined the diagnostic importance of clubbing and the careful consideration of chemotherapy. Although clubbed fingers associated with GISTs are rare, our experience demonstrates the importance of physicians' recognition of clubbing as a paraneoplastic phenomenon for early diagnosis of malignancies since patients seldom notice their own clubbing by themselves...
July 26, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28750235/investigation-of-the-effect-of-plasma-albumin-levels-on-regorafenib-induced-hepatotoxicity-using-a-validated-liquid-chromatography-tandem-mass-spectrometry-method
#7
Yi Yun Pang, Yeong Lan Tan, Han Kiat Ho
Regorafenib is an oral multikinase inhibitor indicated for metastatic colorectal cancer and gastrointestinal stromal tumour. Due to its extensive plasma protein binding and low calculated hepatic extraction ratio, the hepatotoxicity observed with usage of the drug may be related to its plasma exposure. To investigate the highly dynamic free:bound drug concentration for regorafenib in the plasma, a bioanalytical liquid chromatography-tandem mass spectrometric assay was developed and validated in human plasma...
July 17, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/28744850/the-expression-of-hematopoietic-progenitor-cell-antigen-cd34-is-regulated-by-dna-methylation-in-a-site-dependent-manner-in-gastrointestinal-stromal-tumours-gists
#8
Irina Bure, Alexander Braun, Claudia Kayser, Helene Geddert, Inga-Marie Schaefer, Silke Cameron, Michael B Ghadimi, Phillip Ströbel, Martin Werner, Arndt Hartmann, Stefan Wiemann, Abbas Agaimy, Florian Haller, Evgeny A Moskalev
The anatomic site-dependent expression of hematopoietic progenitor cell antigen CD34 is a feature of gastrointestinal stromal tumours (GISTs). The basis for the differential CD34 expression is only incompletely understood. This study aimed at understanding the regulation of CD34 in GISTs and clarification of its site-dependent expression. Two sample sets of primary GISTs were interrogated including 52 fresh-frozen and 134 paraffin-embedded and formalin-fixed specimens. DNA methylation analysis was performed by HumanMethylation450 BeadChip array in three cell lines derived from gastric and intestinal GISTs, and differentially methylated CpG sites were established upstream of CD34...
July 26, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28736068/gastrointestinal-stromal-tumour-and-second-tumours-a-literature-review
#9
REVIEW
Rafael Núñez-Martín, Ricardo Cubedo Cervera, Mariano Provencio Pulla
There are several tumours associated with gastrointestinal stromal tumour (GIST), most of them without an apparent family relationship; only 5% of them occur within the context of a family syndrome. In this article the corresponding literature about the former has been reviewed. A search in Pubmed was carried out, the methodology of which is described in detail in the body of the article. A total of 88 articles have been chosen for the review, next to the application of limits as well as a manual review. GIST patients have a twofold risk of developing a second tumour than the general population (4-33% of them develop a second neoplasm, either synchronic or metachronic)...
July 20, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/28723416/unravelling-the-pharmacologic-opportunities-and-future-directions-for-targeted-therapies-in-gastro-intestinal-cancers-part-2-neuroendocrine-tumours-hepatocellular-carcinoma-and-gastro-intestinal-stromal-tumours
#10
REVIEW
Cindy Neuzillet, Louis de Mestier, Benoît Rousseau, Olivier Mir, Mohamed Hebbar, Hemant M Kocher, Philippe Ruszniewski, Christophe Tournigand
Until the 1990s, cytotoxic chemotherapy has been the cornerstone of medical therapy for gastrointestinal (GI) cancers. Better understanding of the cancer cell molecular biology has led to the therapeutic revolution of targeted therapies, i.e. monoclonal antibodies or small molecule inhibitors directed against proteins that are specifically overexpressed or mutated in cancer cells. These agents, being more specific to cancer cells, were expected to be less toxic than conventional cytotoxic agents. However, their effects have sometimes been disappointing, due to intrinsic or acquired resistance mechanisms, or to an activity restricted to some tumour settings, illustrating the importance of patient selection and early identification of predictive biomarkers of response to these therapies...
July 16, 2017: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28720692/primary-greater-omental-gist-presenting-with-acute-intra-abdominal-haemorrhage
#11
Shariful Islam, Devin Hosein, Vinoo Bheem, Patrick Harnarayan
Primary omental gastrointestinal stromal tumours (GISTs) are classified as extra-GISTs with a reported incidence of <1% of all GISTs. There are only a few cases in the English literature reporting omental GIST with none reporting acute intra-abdominal haemorrhage as a presenting feature. We report a case of a 67-year-old man who presented with haemorrhage from a primary omental GIST requiring emergency laparotomy.
July 18, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28694665/pancreas-preserving-distal-duodenectomy-a-versatile-operation-for-a-range-of-infra-papillary-pathologies
#12
W Kyle Mitchell, Pradeep F Thomas, Abed M Zaitoun, Adam J Brooks, Dileep N Lobo
AIM: To investigate the range of pathologies treated by pancreas preserving distal duodenectomy (PPDD) and present the outcome of follow-up. METHODS: Neoplastic lesions of the duodenum are treated conventionally by pancreaticoduodenectomy. Lesions distal to the major papilla may be suitable for a pancreas-preserving distal duodenectomy, potentially reducing morbidity and mortality. We present our experience with this procedure. Selective intraoperative duodenoscopy assessed the relationship of the papilla to the lesion...
June 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28662235/use-of-pd-1-targeting-macrophage-infiltration-and-ido-pathway-activation-in-sarcomas-a-phase-2-clinical-trial
#13
Maud Toulmonde, Nicolas Penel, Julien Adam, Christine Chevreau, Jean-Yves Blay, Axel Le Cesne, Emmanuelle Bompas, Sophie Piperno-Neumann, Sophie Cousin, Thomas Grellety, Thomas Ryckewaert, Alban Bessede, François Ghiringhelli, Marina Pulido, Antoine Italiano
Importance: There is a strong rationale for treating sarcomas with immunotherapy. Objective: To assess the efficacy and safety of programmed cell death protein 1 (PD-1) targeting in combination with metronomic chemotherapy in sarcomas. Design, Setting, and Participants: This was an open-label, multicenter, phase 2 study of 4 cohorts of patients with advanced soft-tissue sarcoma (STS), including leiomyosarcoma (LMS), undifferentiated pleomorphic sarcoma (UPS), other sarcomas (others), and gastrointestinal stromal tumor (GIST)...
June 29, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28660813/monophasic-synovial-sarcoma-of-the-greater-omentum-case-report-and-review-of-literature
#14
REVIEW
F J Alcalá Serrano, J R Hernández Hernández, T Montenegro Dámaso, E López-Tomassetti Fernández
Synovial sarcoma is a malignant spindle cell neoplasm normally arising from tissues around joints, bursa and tendon sheaths. Several reports involving the gastrointestinal tract, mainly the oesophagus and stomach, have been documented; however, the omentum remains an extremely unusual location. Monophasic type is composed exclusively of spindle cells arranged in fascicles. Establishing the correct diagnosis of these tumours could be challenging because of the similarities with gastrointestinal stromal tumours and other mesenchymal tumours with similar histology...
July 2017: Annals of the Royal College of Surgeons of England
https://www.readbyqxmd.com/read/28658787/gastric-glomus-tumour-misdiagnosed-as-gastric-carcinoid-an-unfamiliar-entity-with-aids-to-diagnosis-and-review-of-literature
#15
Tanush Vig, Mandeep Singh Bindra, Ramani Manoj Kumar, Suceena Alexander
Glomus tumour (GT) is a rare mesenchymal tumour of the stomach with Gastrointestinal Stromal Tumour (GIST), leiomyoma and schwannoma being far more common and comprising more than 90% of all gastric mesenchymal tumours. As glomus bodies are located in the peripheral parts of the human body, these tumours are peripherally located, classically the subungual region, hands, feet and trunk. While being evaluated for renal problems, a middle aged lady was incidentally found to have a gastric tumour. This was submucosal in location and was excised by a wedge resection and reported elsewhere as carcinoid tumour...
May 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28622526/extragastrointestinal-stromal-tumour-of-the-lesser-omentum-a-case-report-and-literature-review
#16
I E Katsoulis, A Tzortzopoulou, P Tziakou, N Arnogiannaki, I Kostoglou-Athanassiou, G Lypas, I G Karaitianos
INTRODUCTION: Extragastrointestinal stromal tumours (EGISTs) are very uncommon compared to their gastrointestinal counterparts. Most of them originate from the intestinal mesentery and the omentum. CASE REPORT: A 70 year-old Caucasian woman presented with a bulky abdominal mass which on laparotomy was found to originate from the lesser omentum and was completely resected. Histological examination revealed spindle cells with severe pleomorphism and high mitotic activity...
2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28584517/a-rare-case-of-mesenteric-gastrointestinal-stromal-tumor-presenting-as-acute-abdomen
#17
Anant Sadanand Ramani, Guruprasad Huske, Francisco P Noronha
Gastrointestinal stromal tumours (GIST) are rare tumours arising from mesenchyme of gastrointestinal tract and overexpress C-kit protein. Mainly seen in stomach and small bowel. Mesenteric GIST are rarely reported as they constitute less than 1% of total GIST. We here report such a rare case of GIST arising from mesentery of small bowel and presenting as acute abdomen. Good surgical clearance ensures good survival whereas incomplete resection results in a high incidence of recurrences with distant metastasis...
January 2017: Nigerian Journal of Surgery: Official Publication of the Nigerian Surgical Research Society
https://www.readbyqxmd.com/read/28557709/influence-of-cytochrome-p450-abc-and-slc-gene-polymorphisms-on-imatinib-therapy-outcome-of-patients-with-gastrointestinal-stromal-tumours-gist
#18
K Wasielewski, B Wasag, A Wozniak, J Pikiel, A Kowalik, C Osuch, E Bylina, J A Siedlecki, P Rutkowski, J Limon
The efficacy of imatinib-based therapy depends on the proteins involved in its metabolism and transportation. Therefore, the aim of our study was to investigate the possible correlation of selected P450, ABC and SLC polymorphic variants and the outcome of imatinib therapy. A total of 101 patients with advanced, KIT/PDGFRA(+) GIST treated with imatinib were enrolled to the study. DNA was extracted from peripheral blood samples and genotypes were determined by PCR-RFLP and direct sequencing. Deviation from the Hardy-Weinberg equilibrium was only observed for rs2740574...
2017: Folia Biologica (Praha)
https://www.readbyqxmd.com/read/28535156/phase-ii-study-of-neoadjuvant-imatinib-in-large-gastrointestinal-stromal-tumours-of-the-stomach
#19
MULTICENTER STUDY
Yukinori Kurokawa, Han-Kwang Yang, Haruhiko Cho, Min-Hee Ryu, Toru Masuzawa, Sook Ryun Park, Sohei Matsumoto, Hyuk-Joon Lee, Hiroshi Honda, Oh Kyoung Kwon, Takashi Ishikawa, Kyung Hee Lee, Kazuhito Nabeshima, Seong-Ho Kong, Toshio Shimokawa, Jeong-Hwan Yook, Yuichiro Doki, Seock-Ah Im, Seiichi Hirota, Seokyung Hahn, Toshirou Nishida, Yoon-Koo Kang
BACKGROUND: Gastrointestinal stromal tumours (GISTs) with high-risk features have poor prognosis even if adjuvant treatment is given. Neoadjuvant imatinib may increase the cure rate by shrinking large GISTs and preserve organ function. METHODS: We conducted an Asian multinational phase II study for patients with gastric GISTs ≥10 cm. Patients received neoadjuvant imatinib (400 mg/day) for 6-9 months. The primary end point was R0 resection rate. RESULTS: A total of 56 patients were enroled in this study...
June 27, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28485054/egfr-gene-mutation-in-gastrointestinal-stromal-tumours
#20
Shan-Shan Shi, Nan Wu, Yan He, Xue Wei, Qiu-Yuan Xia, Xuan Wang, Sheng-Bin Ye, Rui Li, Qiu Rao, Xiao-Jun Zhou
AIMS: The aim of this study was to evaluate the mutation status of epidermal growth factor receptor (EGFR) in gastrointestinal stromal tumours (GISTs) and its association with various clinicopathological variables, as well as to discuss further the effects of EGFR mutations on tumour formation and progression. METHODS AND RESULTS: A well-characterized cohort of 323 GISTs, obtained between 2010 and 2015 from the surgical pathology files of at the Department of Pathology of the Nanjing Jinling Hospital, was screened for mutations in exons 19 and 21 of the EGFR gene...
May 9, 2017: Histopathology
keyword
keyword
37705
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"